#Immunotherapy #FoodAllergy #Peanut
#Desensitization
Peanut allergy is one of the most severe and
persistent food allergies. It affects up to 3% of the pediatric population in
Western countries. It is a major cause of anaphylaxis and has a significant
impact on the quality of life of patients and their families. The constant fear
of accidental exposure causes daily stress, disrupts social life, and imposes
drastic dietary restrictions. To date, management mainly relies on strict
avoidance of the allergen and the use of emergency treatments in case of a reaction—an
approach more focused on risk management than on a curative strategy.
In this context, oral immunotherapy (OIT)
emerges as a promising therapeutic strategy. This approach involves gradually
desensitizing patients through the controlled administration of increasing
doses of peanut, and it is generating significant enthusiasm. However, a
fundamental question remains:
what does it truly mean to “succeed” in OIT
treatment? Clinical trials conducted to date have used widely varying criteria
to define therapeutic success—such as the quantity of peanut tolerated without
reaction, symptom severity, or the occurrence of adverse events. These criteria
are often established by researchers without fully integrating patients'
expectations and priorities. This study was initiated to evaluate how different
definitions of “tolerated dose” affect reported rates of peanut
desensitization.
Numbers... with shifting definitions?
Three randomized controlled clinical trials and
one real-world registry on peanut oral immunotherapy were selected and
analyzed. The aim was to assess how different definitions of the
"tolerated dose" influence reported desensitization rates. To this
end, five tolerance thresholds were defined:
- No
dose-limiting symptoms (DLS) according to PRACTALL criteria or
equivalents;
- No symptoms
limiting activity, defined as absence of CoFAR grade ≥2 symptoms;
- No
non-transient symptoms, allowing short-lived mild symptoms (e.g., oral
pruritus);
- Threshold
without any observed adverse event (objective NOAEL): complete absence of
objective symptoms;
- Absolute
NOAEL (all symptoms considered): even mild or subjective symptoms are
counted as non-tolerated.
Two independent evaluators reclassified
participant data based on these definitions. Inter-rater agreement was
excellent (kappa ≥ 0.82), ensuring high reproducibility of the analysis.
Results show significant variability in success
rates depending on the chosen criteria. For instance, in one trial, the
desensitization rate dropped from
81% under the “DLS” criterion to
49% when
applying the strictest definition, “NOAEL (all symptoms).” This variability
also appeared in intention-to-treat analyses and when tolerance thresholds were
increased (e.g., 10x or 100x the initial threshold).
These findings highlight a crucial reality:
the
apparent success of OIT heavily depends on the evaluation framework used. An
overly permissive definition may overestimate efficacy by accepting
non-negligible symptoms (such as abdominal pain), while an overly rigid one
might underestimate clinically meaningful benefits perceived by patients.
This methodological heterogeneity complicates
comparisons between clinical trials and makes it difficult to inform patients
clearly about what they can realistically expect from treatment. It underscores
the urgent need for a consensus on efficacy assessment criteria in food
immunotherapy.
Read next : Early introduction of gluten to prevent celiac disease
A success that needs clarification
Peanut allergy remains one of the most severe
and persistent forms of food allergy, with a high risk of potentially serious
accidental reactions. While oral immunotherapy offers a promising alternative,
several challenges persist. This study aimed to evaluate how different
definitions of “tolerated dose” influence reported therapeutic success rates in
peanut OIT clinical trials.
Results reveal considerable variability in
desensitization rates depending on the criteria used. This finding shows that
clinical outcomes—often presented as robust—are in fact based on fluctuating
definitions of therapeutic success. It becomes difficult to provide patients
with clear, transparent, and personalized information about expected benefits.
Therefore, urgent efforts are needed to develop
harmonized, validated, reproducible, and patient-centered evaluation criteria.
Future studies should incorporate these parameters into a multidimensional
approach that combines clinical efficacy, quality of life, and perceived
safety. Building international consensus on the definition of “tolerated dose”
will be crucial to making OIT a credible, understandable, and clinically
relevant therapeutic approach.
Read next: Allergies: could the gut hold the key?
